



ImExHS Limited – (ASX: IME)
CORPORATE PRESENTATION

**Leading Medical Imaging Solutions
Company Currently Operating in 11
Countries in LatAm.**


5 March 2019

- Established next generation Radiology and Imaging Software platform
- IME founded in 2012
- Current operations in Colombia, Peru, Mexico, Ecuador and Costa Rica.
- 18 distributors in 11 countries
- \$19.8m of total contracted revenue - January 2019
- Ongoing expansion into neighbouring LATAM countries with low risk go-to-market strategy
- First collaboration in Australia under testing H1 2019.
- Additional cutting-edge functionality implemented- Web MPR/Web 3D & MIP - Two pilot sites deployed Q4 2018, full commercial release Q1 2019.
- Applied for FDA approval in 2018, ahead of USA soft launch in H1 2019


Solutions are Fully Developed, Validated & In Operation

- ImExHS has deployed >200 sites in LATAM
- 18 distributors covering 11 Countries
- Used by over 600 Radiologists
- > 35,000 clinical devices
- 71 Hospitals
- 180 Clinics
- 216 Customers
- > 5 million new radiological studies per annum

Total Contracted Value
(AUD Equivalent)



Annualised Recurring Revenue
(AUD Equivalent)






- Escalating healthcare costs in all markets are driving demand for cost effective solutions and outsourcing
- Large percentage of radiology systems in developing countries use archaic analogue work flows, creating churn event opportunity to migrate to next-generation digital cloud solution
- Demand for web-based TeleRadiology is growing rapidly (predicted CAGR of 21%²)
- The application of Artificial Intelligence to radiological interpretation creates opportunities on numerous fronts
- ImExHS is initially targeting sales expansion into LATAM markets neighbouring existing operations, followed closely by APAC (Australia and Philippines), then North America and finally Europe

GEOGRAPHY	MARKET (US\$m) ¹	GROWTH (CAGR) ¹
LATAM	417	8.1%
APAC	695	7.0%
North America	1,667	4.4%
Europe	967	5.8%
Other	236	6.8%
TOTAL	3,982	5.8%

¹ Acute Market Report (2015), Picture Archiving Communication Systems (PACS) & Radiology Information Systems (RIS), Growth, Future Prospects & Competitive Analysis, 2016 - 2026

² Future Market Insights (2017), Global Teleradiology Market Industry Analysis and Opportunity Assessment, 2016-2026



¹ Tele-Radiology - radiology concerned with the transmission of digitised medical images (as X-rays, CT scans, and sonograms) over electronic networks and with the interpretation of the transmitted images for diagnostic purposes

Modular

Able to grow and scale as scan volumes increase and as new diagnostic scanners or radiology facilities are added

Independent System

Hiruko can run on any infrastructure - private or public cloud and even on the customer's own dedicated server infrastructure

API Enabled

Easy to integrate with other customer or third party systems to extend its value in the customer environment

.... Compared to most RIS PACS solutions which are built on heavy, inflexible and expensive client server architecture.



Hiruko supporting the efficiency and user experience for Radiologists

- Radiologists can
 - work from anywhere, on any device or browser
 - customise Hiruko to their own requirements and preferences
- The fully integrated nature of Hiruko increases both the speed and efficiency of the Radiology workflow
 - No need for the Radiologist to jump between different applications and windows
 - Second opinions can be sought from Colleagues regardless of what platform they use
- The Radiologist can use voice recognition (clinical language understanding) to append the diagnosis to the image, from anywhere on any device
- Hiruko has integrated billing including support for publically funded health insurance programs (similar to Medicare)



Radiology businesses (hospitals & clinics) prefer the ImExHS Hiruko platform because:

- Exceeds the capability & usability of competing high end platforms – Integrated Business Intelligence
- Disruptive price point – up to 75% cheaper than competitors
- Cloud-based with zero in-house IT impact
- Single end to end solution including integrated scheduling and billing tools; avoid integration of multiple solutions
- Supports non-standard file formats that have clinical significance

Radiologists love the ImExHS Hiruko platform because they can:

- Work from anywhere, using any device (Mac, PC, tablet or smartphone)
- Use speech recognition with full Clinical Language understanding embedded in the application
- Use post-processing of images to aid in diagnosis
- Efficiently consult with colleagues for second opinions
- Hiruko software is fast, stable and easy to access



Revenue Contract Models



1. Software as a Service (SaaS)
3-5 year contacts (paid monthly)



2. Platform as a Service (PaaS)
3-5 year contacts (paid monthly)



3. One-off Sales & Maintenance
Paid in Full

Target Geographies

LATAM
(Now)

APAC
(Next)

Australia, USA, and
Europe (market driven)

Target Markets

HEALTH CARE FACILITIES

—
Private Hospitals & Clinics

Public Hospitals & Clinics

Private Practices

Target Verticals

Radiology

Anatomical Pathology (APLIS)

Cardiology

Security Body Scanning (new)

Distribution Model

DIRECT SALES

—
Global Growth developing
branches in each new country

Cloud Market Place Globally

Augment with channel strategy

CHANNELS

—
Specialist Distributors

TELCOs


OEMs

White Label

ImExHS Today – Channel Partners



New Product Verticals



Commercialisation

- RADIOLOGY**
 Q4 2018 Web 3D MPR & MIP, triangulation tool implemented. 2 Pilot sites deployed.
 Q1 2019 released.
- ANATOMICAL PATHOLOGY**
 Q4 2017 Secured first commercial customer
 Q3 2018 2nd Pilot test customer commenced
 Q1 2019 Full Commercial launch
- CARDIOLOGY**
 Q1 2018 Pilot testing at Las Americas (VNA installed)
 Q3 2018 Develop information work platform
 Q1 2019 Commercial launch

Artificial Intelligence

- NATURAL LANGUAGE PROCESSING ALGORITHMS
Specified pathologies
Predictive Diagnostic alerts
Diagnostic concordance analysis
- MACHINE LEARNING ALGORITHMS
Tumour Segmentation and Classification
Lung Nodule detection
Bone Fracture severity identification
- AUTOMATIC IMAGE ANNOTATION
RECOMMENDATIONS


Research

- BRAVIZ v2.0
Platform for advanced analytics and visualisation of neurological images
- NEW VISUALISATION TOOLS
Analytics on visual presentation



	2018	2019			
	Q4	Q1	Q2	Q3	Q4
LATAM					
Brazil		Appoint Distributor		Launch	
Other South America		Appoint Distributor	Launch		
Other Central America	Appoint Distributor	Launch			
APAC					
Phillipines		Appoint Distributor		Launch	
Australia	Pilot				
APAC 2				Release	
APAC 3				Release	
NORTH AMERICA					
FDA	Submit	Approval			
USA			Soft Launch		

Medical Imaging Corporate Activity





DE-RISKED	High margin contracted future revenues from core SaaS model
LEADING TECHNOLOGY	Next generation workflow and image management solution for healthcare facilities, built by radiologists, for radiologists
PROVEN	Successfully demonstrated market penetration into Mexico, Ecuador, Peru and Costa Rica with post-raising strategies for rapid expansion in other LATAM and Asia-Pacific
SALES PIPELINE	Strong sales pipeline, including renewals will add to existing contracted revenue, no customer churn
FUNDING	Funding largely dedicated to core business expansion, rather than technical development



	VOLPARA (ASX:VHT)	PRO MEDICUS (ASX:PME)	ImExHS (ASX:IME)
Description	Breast X-ray imaging, transitioning to SaaS based contracts	Radiology imaging software, strong 5 year contracted revenue order book	Radiology imaging software, High growth SaaS based revenue
Market Cap	\$199m ¹	\$1,500m ¹	\$22m ¹
TRADING MULTIPLES			
Total Contracted Value (TCV)	n/a [*]	\$135m ³	\$20m ²
TCV Multiple	n/a	10.5x	1.1x
Annualised Recurring Revenue (ARR)	\$5.3m ²	\$29.1m ³	\$4.3m ²
ARR Multiple	37.3x	51.5x	5.2x

Notes:

1. 4 Mar 2019 (Source: ASX)
2. 31 Dec 2018 (Sources: VHT-4C Announcement, PME-4D Announcement)
3. 30 Jun 2018 (Source: PME-Annual Report)

* Not applicable as TCV definition is not comparable

Capital Table and Summary Financials



OVERVIEW CAP TABLE

Market Price	\$0.025
Market Cap	\$22m
Shares on Issue:	925.7m
Quoted	395.7m
Escrowed (12-24m)	530m
Milestone Options (two tranches)	100m
Options	133.5m

Financial at FYE 31 December 2018 – A\$m

Revenue	\$6.1m	+ 70% yoy
Cash	\$2.4m	n/a
Trade & Other Receivables	\$3.9m	n/a
Total Contract Value (TCV)	\$20m	+343% yoy
Annual Recurring Revenue (ARR)	\$4.3m	+115% yoy
Trade & Other Payables	\$1.9m	n/a
Net Loss	(\$4.9m)*	
Total Equity	\$5.9m	+ 818%

* The transaction cost and share based payments related to the acquisition and relisting of IME during 2018 totalled \$3.93m.

Board & Key Management



TOM PASCARELLA Chairman

Company Director

- Experienced professional in Corporate & Investment Banking, focused on Credit Products, Structured Finance and M&A Advisory services. Since his time in banking, with Allen Partners Tom has focused on capital raising for asset managers and SMEs.
- Former CEO and Managing Director of Bank of America N.A. Sydney Branch.
- Fellow FinSIA, (Financial Services Institute of Australasia)
- Member of the Australian Institute of Company Directors

DR. GERMAN ARANGO CEO, Director

Professor of Neuro-Radiology

- Entrepreneur with > 10 years experience running Radiology businesses
- ImExHS Founder

CARLOS PALACIO Non-Executive Director

Founder and CEO of CrossPoint Telecommunications

- Managed IT and Cloud provider to multinationals across 42 countries
- Major investor in ImExHS to date.
- B Eng, MBA (Macquarie)

Dr Douglas Lingard Non-Executive Director

Experienced Radiologist and Nuclear Physician. Co-founder of Pittwater Radiology Partners which listed on the ASX and became the largest supplier of radiology services in Australia and a major supplier of diagnostic imaging to the NHS in the United Kingdom.

HOWARD DIGBY Non-Executive Director

Company Director

- 25 year experience managing technology related businesses across Asia Pacific region
- Senior management roles at Adobe, Gartner, Economist Group
- B Eng (Hons) (UWA)

ANDRES VANEGAS Chief Sales Officer

Mechatronic Engineer

- Specialist project and service manager in Radiology industry
- Over 10 years experience in deployment of imaging solutions for healthcare
- Ex-CTO Fujifilm Colombia

DR. JORGE MARIN Chief Medical Officer

Professor of Neuro-Radiology

- Surgeon & Neuro-Radiologist Barcelona & Bogota
- Manages ImExHS's University collaboration business agreements


The information contained in this Presentation or subsequently provided to the Recipient of this Presentation, whether orally or in writing by or on behalf of ImExHS Limited or its respective employees, agents or consultants ("Information") is provided to the Recipient on the terms and conditions set out in this notice.

The Recipient should not treat the Information as advice relating to legal, taxation, financial product or investment matters and should consult their own advisers. This Presentation does not purport to contain all the information that a prospective investor may require. The Information may not be appropriate for all persons and it is not possible for ImExHS Limited to have regard to the investment objectives, financial situation and particular needs of each Recipient who reads or uses the Information. Accordingly, no recommendation or expression of opinion is contained within the Information. Further, no representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the Information, including the likelihood of achievement or reasonableness or any forecasts, prospects or returns contained in the Information. Before acting in reliance on any Information, the Recipient should conduct their own investigation and analysis in relation to the investment opportunity presented by this Presentation and should check the accuracy, reliability and completeness of the Information and obtain independent and specific advice from appropriate professional advisers.

Statements contained in the Information, particularly those regarding possible or assumed future performance or potential growth, prospects or projections of ImExHS Limited are, or may be, forward looking statements. Such statements relate to future events and expectations and, as such, involve known and unknown risks, uncertainties and contingencies. The Information may also be subject to clarification and change and ImExHS Limited may in its absolute discretion, but without being under any obligation to do so, update, amend or supplement the Information.

The Information is for informational purposes only and does not constitute an offer to issue, or arrange to issue, securities or other financial products. The Information is not, and should not be construed to be, a Prospectus.

To the maximum extent permitted by law none of ImExHS Limited or its respective employees, agents or consultants nor any other person accepts any liability, including, without limitation, any liability arising out of fault of negligence, for any loss arising from the use of the Information.





Thank You

ime**><**HS